May 8th 2024
In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...
1.5 Credit / Hematology, Oncology
View More
Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals
1.0 Credit / Hematology, Oncology
View More
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy
1.5 Credits / Oncology, Hematology, Hematologic Cancer
View More
Rare Risk of Acquired Hemophilia A Seen Following COVID-19 Infection, Vaccination
March 11th 2023A group of researchers detailed a case of acquired hemophilia A (AHA) following infection and again following vaccination, and provided additional insights through their systematic review of available data.
Read More
FVIII Half-life in Patients With Hemophilia Largely Determined by Clearance of VWF
March 10th 2023These new findings suggest that variability in factor VIII (FVIII) half-life in patients, though impacted by all 3 factors, is largely attributed to variability in the clearance of endogenous von Willebrand factor (VWF).
Read More
Andexanet Alfa Fully Neutralizes Anticoagulation From Thrombotic Disorder Treatment
February 22nd 2023Researchers found that the anticoagulant effects of apixaban, betrixaban, edoxaban, and rivaroxaban were partially neutralized at an andexanet alfa dose of 50 mcg/mL and were completely neutralized at 100 mcg/mL.
Read More
FVIII Inhibitory Antibody Titer Shows Implications for Response to IST Treatment for AHA
February 13th 2023Data show that patients who have factor VIII (FVIII) inhibitor titers of 20 or higher BU/mL took longer to achieve complete responses (CR) and had lower CR rates vs patients with lower titers.
Read More
Despite High False-Positive Rate of FIT, Patients With Hemophilia Have High CRC Detection Rate
February 11th 2023The researchers underscored the importance of their findings for a wide group of patients with inherited bleeding disorders, as most colorectal cancer (CRC) screening programs across the globe use fecal immunochemical testing (FIT).
Read More
Safety and Efficacy of New Hemophilia Treatments Are Most Important, Patients Report
December 7th 2022Safety and efficacy were the most important factors for patients with hemophilia learning about gene therapies, although more research is needed to see how collaboration between providers and patients contributes to the best outcomes.
Read More
NSAIDs May Be Safe for Use in Hemophilia, but More Research Is Needed
November 11th 2022The hesitation to prescribe nonsteroidal anti-inflammatory drugs (NSAIDs) to patients with hemophilia is not supported by current research, based on a recently published review, but the available studies had significant limitations.
Read More
Cost-Savings Model Estimates Reduced Economic Burden With Gene Therapy for Hemophilia A
November 6th 2022Gene therapy is a novel approach to hemophilia A treatment that carries a substantial cost up front but may lead to cost savings compared with current prophylaxis agents in the long run.
Read More
ICER Releases Draft Evidence Report on Gene Therapies for Hemophilia A and B
September 17th 2022Despite $2.5 million placeholder price tags, the Institute for Clinical and Economic Review draft evidence report considers gene therapy cost-effective versus comparators in both hemophilia A and B.
Read More
Review Looks at Impact of SDOH on Bleeding Disorders
September 9th 2022More than 3 million Americans have inherited bleeding disorders, and social determinants of health (SDOH) play a role in a number of ways, including cost for treatment, difficulty accessing specialists, educational barriers, and more.
Read More
Case Study Chronicles Onset and Treatment of Acquired Hemophilia A Following HSCT for ALL
September 6th 2022The case emphasizes the importance for clinician awareness of the potential for rare immune-mediated disorders, including acquired hemophilia A (AHA), following allogeneic hematopoietic stem cell transplantation (HSCT).
Read More
Systematic Approaches to Patient Educational Needs May Benefit Those With Bleeding Disorders
September 2nd 2022Nurse-led education is an essential aspect of care for patients with bleeding disorders, but there is currently a lack of research on specific strategies to improve patient self-management through education.
Read More